Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best cancer stocks to invest in now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts. Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval ldutko/Shutterstock.com In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib in patient ...

Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules. Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development David Smart/Shutterstock.com The ultimate goal is to develop a targeted oncology platform for small molecules that can overcome resistance and ...

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones. Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key ...

Core Insights - Schrodinger Inc. is recognized as a promising investment in the cancer sector, showcasing strong revenue growth and a strategic shift towards a licensing model for more predictable revenue streams [1][3]. Financial Performance - Full-year revenue for 2025 increased by 23.3% to $255.9 million, with software revenue rising by 10.6% [3]. - Drug discovery revenue more than doubled to $56.4 million from $27.2 million in the previous year [3]. - Fourth-quarter revenue decreased by 1.2% year-over-year to $87.2 million, primarily due to a 13% decline in software revenue to $69.3 million [3]. - Drug discovery revenue in the fourth quarter surged to $18 million, up from $8.7 million in the same quarter of the prior year [3]. Profitability and Loss - The company's net loss for the full year decreased to $103.3 million from $187.1 million in 2024 [4]. - Schrodinger achieved profitability in the fourth quarter of FY25, reporting a net income of $32.5 million compared to a net loss of $40.2 million in the fourth quarter of 2024 [4]. Future Guidance - For 2026, the company projects software revenue between $218 million and $228 million, indicating a growth of 10-15% [5]. - Drug discovery revenue is anticipated to be in the range of $55 million to $65 million [5]. Company Overview - Schrodinger, Inc. operates as a healthcare technology company, providing a physics-based software platform for molecular simulation aimed at accelerating drug development and materials science [6].

Nuvation Bio Inc. (NYSE:NUVB) is one of the best cancer stocks to invest in now. On February 9, Nuvation Bio Inc. (NYSE:NUVB) finalized a protocol amendment to an ongoing global SIGMA study of safusidenib. The company is evaluating the efficacy and safety of safusidenib in patients with high-risk or high-grade IDH1-mutant astrocytoma. Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma The amended protocol expands patient eligibility in the registration portion of the trial. It ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials. Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab In addition, the company has engaged GORTEC, a European Head and Neck Oncology and ...

Janux Therapeutics Inc. (NASDAQ: JANX) is one of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc. (NASDAQ:JANX) commenced patient dosing in the Phase 1 study of JANX011. The company has already dosed the first patient in the trial evaluating JANX011 for the treatment of autoimmune diseases. Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial Pixabay/Public Domain The candidate drug is designed to enable deep and durable immune reset by ...

Repurchase of Truecaller B shares in week 9, 2026 [Accessibility Statement] Skip NavigationSTOCKHOLM, March 2, 2026 /PRNewswire/ -- During week 9, 23-27 February 2026, Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 2,000,000 own B shares (ISIN: SE0016787071), corresponding to 0.57% of outstanding capital. Since the start of the current program Truecaller has bought back 12,659,594 shares, corresponding to 3.58% of outstanding capital.The share buybacks form part of the share b ...

Robert W. Stallings, a director at Texas Capital Bancshares (NASDAQ:TCBI), a major Texas-based commercial lender, reported the purchase of 40,000 shares of Depositary Shares for Series B Preferred shares through multiple transactions on Feb. 23 and Feb. 24, 2026, as disclosed in a SEC Form 4 filing. Transaction summary Metric Value Shares traded 40,000 Transaction value ~$888,000 Post-transaction shares (direct) 289,961 Post-transaction shares (indirect) 90,039 Post-transaction ...

Among the banks that received the threats were the The six schools that received similar threat emails included Army Public School in Delhi Cantt, Salwan Public School, Sardar Patel Vidyalaya, Mira Public School in Janakpuri, Ramjas Public School and Ramjas School in Rajendra Nagar. According to the DFS, calls regarding bomb threats started coming in from 8.20 am, following emails received by the institutions. "Teams from the local police, bomb disposal squad, dog squad and fire department were immediatel ...